tiprankstipranks
NccRCC ‘material expansion opportunity’ for Exelixis, says William Blair
The Fly

NccRCC ‘material expansion opportunity’ for Exelixis, says William Blair

After Exelixis (EXEL) announced initiation of the Phase III STELLAR-304 trial of zanzalintinib in combination with Bristol-Myers’ (BMY) Opdivo in frontline advanced non-clear cell renal cell carcinoma, or nccRCC, William Blair analyst Andy Hsieh said he believes that the nccRCC market represents a "material expansion opportunity" for the zanzalintinib franchise. He estimates the global market in nccRCC "to be north of $1 billion commercially," added Hsieh, who has an Outperform rating on Exelixis shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on EXEL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles